Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

RELEVANCE data sheds light on follicular lymphoma treatment

Morschhauser F et al. N Engl J Med. 2018;379:934-47.

Key clinical point: Rituximab plus lenalidomide was as effective as rituximab with chemotherapy but with a different safety profile.

Major finding: Complete responses were seen in 48% of rituximab/lenalidomide patients versus 53% in the rituximab/chemotherapy patients (P = .13).

Study details: A phase 3 superiority trial of 1,030 patients with previously untreated follicular lymphoma.

Disclosures: Celgene and the Lymphoma Academic Research Organization funded the study. The authors reported various disclosures, including financial ties to Celgene.

Read the article.

Citation:

Morschhauser F et al. N Engl J Med. 2018;379:934-47.

This Week's Must Reads

Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.

Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.

Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.

Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.

Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

Must Reads in Follicular Lymphoma

Long-term data on R-CHOP in follicular lymphoma, Wantanabe T et al. Lancet Haematol. 2018 Nov;5(11):e520-31

Positive results for rituximab biosimilar in comparative trial, Ogura M et al. Lancet Haematol. 2018 Nov;5(11):e543-53

5F9 plus rituximab looks durable in NHL, Advani R et al. N Engl J Med. 2018;379:1711-21

Long-term data on chemo-free approach in advanced indolent lymphoma, Lockmer S et al. J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262

Watchful waiting in follicular lymphoma, Davies GA et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 28. doi: 10.1016/j.clml.2018.08.015